Company intelligence / Profile preview

RubrYc Therapeutics

San Carlos, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

RubrYc Therapeutics developed a proprietary AI-powered Discovery Engine to identify epitope-selective mono and bispecific antibodies, focusing on hard-to-target subdominant/conformational epitopes. The company’s lead program targeted CD25 with an IL‑2 sparing anti-CD25 antibody aimed at depleting regulatory T cells without affecting effector T cell function. At the time of its acquisition by iBio in September 2022, RubrYc had several preclinical immuno-oncology candidates but no reported clinical results or late-stage programs.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Bispecific antibodies
Industry: Biotech

Drug pipeline

1 asset

RTX-003/IBIO-101

Pre-clinical

Indications: Cancer

Partnerships

Zai Labs – research collaboration and license option agreement prior to acquisition

Beyond the preview

Go deeper on RubrYc Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RubrYc Therapeutics.

Explore the full profile